Laddar...
Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer
The PROfound trial highlights that there is a benefit in testing genes involved in homologous recombination (HR) and forms the rationale for testing in all patients with metastatic, castration-resistant prostate cancer (mCRPC). This trial also demostrates that olaparib improves progression free surv...
Sparad:
| I publikationen: | Cancer Biol Ther |
|---|---|
| Huvudupphovsmän: | , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Taylor & Francis
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7583699/ https://ncbi.nlm.nih.gov/pubmed/32844710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2020.1809913 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|